EUVIMEDEUVIMED entdecken
Crossref

Patient preferences regarding medical treatment options in eosinophilic esophagitis

P. Schreiner, B. Morell, H. Schlager, H. Gröchenig, K. Steidl, F. Murray, L. Biedermann

Zeitschrift für Gastroenterologie · 01.05.2024 · 62 (05) · e491

DOI: 10.1055/s-0044-1786915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.05.2024. Verfasst von P. Schreiner und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Until a few years ago, there existed only off-label medical treatment options for eosinophilic esophagitis (EoE) such as proton pump inhibitors (PPI) or swallowed topical corticosteroids (STC) with various formulations and ingredients. Since the approval of a budesonide orodispersible tablet (BOT), the first biological agent (Dupilumab) has been approved by the EMA and FDA, and another budesonide oral suspension has been received approval by the FDA recently. Currently, many phase 3 trials with different drugs are running, resulting in various treatment options in the next years. However, data about patients’ perspectives are lacking. We therefore aimed to assess patients’ awareness, beliefs and restrictions to medical treatment options in EoE Methods: We developed a web-based survey using SurveyMonkey and sent a questionnaire comprised of 47 questions about patients’ preferences regarding medical treatment options to patients with established EoE in Switzerland, Austria and Germany.

Results

A total of 56 patients (64% male, 66% with other atopic diseases) from Switzerland (64%), Austria (34%) and Germany (2%) answered the questionnaire. A swallowed topical therapy was ranked first (71% of patients) in terms of patient’s preference followed by a subcutaneous therapy every 4 weeks (21.4%) and by an oral therapy with systemic effect (7%). Although one third do not have reservations against long-term medical therapy, nearly half of patients (42%) are skeptical about long-term treatment and 65% are afraid of adverse events. However, a third of patients are not aware that STC are locally effective medications with nearly no systemic effect. Furthermore, 48% of patients believe that physicians underemphasize adverse events of medication. Nearly all patients understand the importance of not only treating symptoms but also inflammation (85%).

Conclusion

Patients with EoE prefer topical agents over other available routes of administration. Patient education should be carried out to address reservations about long-term treatment. Publication History Article published online: 05 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Schreiner, P., Morell, B., Schlager, H., Gröchenig, H., Steidl, K., Murray, F., & Biedermann, L. (2024). Patient preferences regarding medical treatment options in eosinophilic esophagitis. Zeitschrift für Gastroenterologie, 62(05), e491. https://doi.org/10.1055/s-0044-1786915

Vancouver

Schreiner P, Morell B, Schlager H, Gröchenig H, Steidl K, Murray F, et al. Patient preferences regarding medical treatment options in eosinophilic esophagitis. Zeitschrift für Gastroenterologie. 2024;62(05):e491. doi:10.1055/s-0044-1786915

BibTeX
@article{Schreiner2024,
  author = {Schreiner, P. and Morell, B. and Schlager, H. and Gröchenig, H. and Steidl, K. and Murray, F. and Biedermann, L.},
  title = {Patient preferences regarding medical treatment options in eosinophilic esophagitis},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2024},
  volume = {62},
  number = {05},
  pages = {e491},
  doi = {10.1055/s-0044-1786915}
}
Kostenlos starten →